NYXTHRACIS

This brand name is authorized in Austria, Croatia, Estonia, Italy, Lithuania, Poland.

Active ingredients

The drug NYXTHRACIS contains one active pharmaceutical ingredient (API):

1	Obiltoxaximab UNII 29Z5DNL48C - OBILTOXAXIMAB
	Obiltoxaximab is a monoclonal antibody that binds the protective antigen (PA) of B. anthracis. Obiltoxaximab inhibits the binding of PA to its cellular receptors, preventing the intracellular entry of the anthrax lethal factor and oedema factor, the enzymatic toxin components responsible for the pathogenic effects of anthrax toxin.
	Read more about Obiltoxaximab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
NYXTHRACIS Concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J06BC04		J Antiinfectives for systemic use → J06 Immune sera and immunoglobulins → J06B Immunoglobulins → J06BC Antibacterial monoclonal antibodies
Discover more medicines within J06BC04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1833678
IT	Agenzia del Farmaco	049226018
LT	Valstybinė vaistų kontrolės tarnyba	1091351